CAMOIP

CAMOIP performs comprehensive integration and analysis of multi-omics data to evaluate immune checkpoint inhibitor (ICI) responses and immunogenomic features across pan-cancer cohorts.

Key Features:

• Multi-Omics Integration: Integrates mutation profiles, gene expression levels, prognostic and clinical data across pan-cancer cohorts.
• Survival Analysis: Performs survival analysis to identify prognostic markers associated with ICI therapy.
• Expression Analysis: Assesses gene expression patterns across different cancer types and treatment responses.
• Drug Sensitivity Analysis: Analyzes tumor drug sensitivity data to correlate molecular features with therapeutic response.
• Mutational Landscape Analysis: Characterizes mutation profiles associated with immunotherapy outcomes.
• Immune Checkpoint Analysis: Examines expression and alterations of immune checkpoint genes in relation to ICI response.
• Immune-Related Signature Analysis: Identifies immune-related gene signatures correlated with patient responses to ICIs.
• Immune Cell Analysis: Analyzes the composition and function of immune cells within the tumor microenvironment.
• Immune Gene Analysis: Investigates genes involved in immune regulation and their impact on therapy efficacy.
• Immunogenicity Analysis: Assesses tumor immunogenicity and the potential to elicit immune responses.
• Gene Set Enrichment Analysis (GSEA): Performs GSEA to identify enriched gene sets and pathways relevant to immunotherapy.
• Large-Scale Data Handling: Processes multi-omics data from over 4,000 patients to support statistically powered analyses.

Scientific Applications:

• Candidate Drug Target Identification: Enables identification of candidate drug targets through comprehensive biomarker screening.
• Prognostic Marker Discovery: Supports discovery of prognostic markers that predict patient outcomes under ICI therapy.
• Mechanistic Studies of Immune Checkpoint Therapy: Facilitates investigation of mechanisms underlying ICI response and resistance to guide therapeutic strategy development.

Methodology:

Integrates and analyzes large-scale multi-omics datasets (mutation profiles, gene expression, prognostic/clinical data) and applies analyses explicitly including survival analysis, gene set enrichment analysis (GSEA), mutational landscape characterization, drug sensitivity analysis, and immune cell/signature analyses to identify patterns and correlations between genetic mutations, gene expression, immune responses, and clinical outcomes.